[Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002].
Inserm U. 453, Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.
Isabelle
I
Ray-Coquard
Jean-Yves
JY
Blay
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D018223:Dermatofibrosarcoma / Q000188:drug therapy; D005431:Florida; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use*; D012509:Sarcoma / Q000188:drug therapy / Q000235:genetics; D012878:Skin Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D019009:Proto-Oncogene Proteins c-kit